---
figid: PMC7299245__40265_2020_1341_Fig1_HTML
figlink: pmc/articles/PMC7299245/figure/Fig1/
number: F1
caption: Targets of new therapeutic options in beta-thalassemia. a SMAD2/3 signaling
  pathway is the target of activin receptor ligand trap molecules. Members of the
  transforming growth factor β (TGF-β) superfamily ligands binding leads to the multimerization
  of type I and type II receptors. Upon the activation of the type I receptor, phosphorylation
  of SMAD2/SMAD3 takes place. This leads to dissociation from the type I receptor
  and oligomerization with SMAD4 to form a complex that translocates into the nucleus,
  thereby regulating the gene and promoting a cellular response with inhibition of
  late-stage erythropoiesis. Luspatercept and sotatercept prevent the binding of the
  ligand, thus inhibiting this pathway and promoting late-stage erythropoiesis. b
  JAK2/STAT5 signaling pathway is the target of JAK2 inhibitors, e.g., ruxolitinib.
  In β-thalassemia, erythropoietin (EPO) synthesis is increased, leading to activation
  of the JAK2/STAT5 pathway, thus altering the proliferation and differentiation of
  the erythroid progenitors. c Regulation of hepcidin expression in hepatocytes is
  the target of mini-hepcidin and TMPRSS6 inhibitors. The binding of bone morphogenetic
  protein 6 (BMP6) and hemojuvelin (HJV) to the BMP6 receptor leads to a downstream
  signaling mechanism via SMAD1, SMAD5, or SMAD8, which activate SMAD4. SMAD4 will
  then stimulate the transcription and expression of hepcidin (encoded by HAMP). The
  SMAD signaling pathway is also regulated by other molecules like transferrin receptor
  2 (TFR2) upon its association with human hemochromatosis protein (HFE) and HJV.
  Transmembrane protease serine 6 (TMPRSS6) negatively modulates HAMP expression by
  cleaving HJV from the cell surface. The secretion of erythroferrone (ERFE) inhibits
  hepcidin expression, the signaling pathway of which is currently unknown. The administration
  of synthetic hepcidins and the inhibition of TMPRSS6, which ultimately increases
  hepcidin expression, result in ferroportin internalization and iron restriction.
  Ferroportin inhibitors (not shown) are another class of drugs that induce iron restriction
  (see Sect. )
pmcid: PMC7299245
papertitle: 'Beta Thalassemia: New Therapeutic Options Beyond Transfusion and Iron
  Chelation.'
reftext: Irene Motta, et al. Drugs. 2020 Jun 15 :1-11.
pmc_ranked_result_index: '8609'
pathway_score: 0.9540325
filename: 40265_2020_1341_Fig1_HTML.jpg
figtitle: Targets of new therapeutic options in beta-thalassemia
year: '2020'
organisms: Homo sapiens
ndex: ''
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC7299245__40265_2020_1341_Fig1_HTML.html
  '@type': Dataset
  description: Targets of new therapeutic options in beta-thalassemia. a SMAD2/3 signaling
    pathway is the target of activin receptor ligand trap molecules. Members of the
    transforming growth factor β (TGF-β) superfamily ligands binding leads to the
    multimerization of type I and type II receptors. Upon the activation of the type
    I receptor, phosphorylation of SMAD2/SMAD3 takes place. This leads to dissociation
    from the type I receptor and oligomerization with SMAD4 to form a complex that
    translocates into the nucleus, thereby regulating the gene and promoting a cellular
    response with inhibition of late-stage erythropoiesis. Luspatercept and sotatercept
    prevent the binding of the ligand, thus inhibiting this pathway and promoting
    late-stage erythropoiesis. b JAK2/STAT5 signaling pathway is the target of JAK2
    inhibitors, e.g., ruxolitinib. In β-thalassemia, erythropoietin (EPO) synthesis
    is increased, leading to activation of the JAK2/STAT5 pathway, thus altering the
    proliferation and differentiation of the erythroid progenitors. c Regulation of
    hepcidin expression in hepatocytes is the target of mini-hepcidin and TMPRSS6
    inhibitors. The binding of bone morphogenetic protein 6 (BMP6) and hemojuvelin
    (HJV) to the BMP6 receptor leads to a downstream signaling mechanism via SMAD1,
    SMAD5, or SMAD8, which activate SMAD4. SMAD4 will then stimulate the transcription
    and expression of hepcidin (encoded by HAMP). The SMAD signaling pathway is also
    regulated by other molecules like transferrin receptor 2 (TFR2) upon its association
    with human hemochromatosis protein (HFE) and HJV. Transmembrane protease serine
    6 (TMPRSS6) negatively modulates HAMP expression by cleaving HJV from the cell
    surface. The secretion of erythroferrone (ERFE) inhibits hepcidin expression,
    the signaling pathway of which is currently unknown. The administration of synthetic
    hepcidins and the inhibition of TMPRSS6, which ultimately increases hepcidin expression,
    result in ferroportin internalization and iron restriction. Ferroportin inhibitors
    (not shown) are another class of drugs that induce iron restriction (see Sect. )
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - GDF3
  - GDF10
  - TGFB3
  - ACTA1
  - MSTN
  - TGFB1
  - ACTC1
  - GDF11
  - GDF1
  - ACTB
  - TGFB2
  - ACVR1B
  - TGFBR1
  - ACVR1C
  - SMAD2
  - SMAD3
  - SMAD4
  - EPO
  - JAK2
  - STAT5A
  - STAT5B
  - BMP6
  - HFE
  - HFE2
  - MT2A
  - TFR2
  - TFRC
  - SMAD1
  - SMAD5
  - SMAD9
  - JAK1
  - JAK3
  - TYK2
  - IL6
  - STAT3
  - HAMP
  - ERFE
  - Fe (III)
genes:
- word: GDF3
  symbol: GDF3
  source: hgnc_symbol
  hgnc_symbol: GDF3
  entrez: '9573'
- word: GDF10
  symbol: GDF10
  source: hgnc_symbol
  hgnc_symbol: GDF10
  entrez: '2662'
- word: TGF-B3
  symbol: TGFB3
  source: hgnc_symbol
  hgnc_symbol: TGFB3
  entrez: '7043'
- word: ActA
  symbol: ACTA
  source: hgnc_prev_symbol
  hgnc_symbol: ACTA1
  entrez: '58'
- word: GDF8
  symbol: GDF8
  source: hgnc_prev_symbol
  hgnc_symbol: MSTN
  entrez: '2660'
- word: TGF-B1
  symbol: TGFB1
  source: hgnc_symbol
  hgnc_symbol: TGFB1
  entrez: '7040'
- word: ActC
  symbol: ACTC
  source: hgnc_prev_symbol
  hgnc_symbol: ACTC1
  entrez: '70'
- word: GDF11
  symbol: GDF11
  source: hgnc_symbol
  hgnc_symbol: GDF11
  entrez: '10220'
- word: GDF1
  symbol: GDF1
  source: hgnc_symbol
  hgnc_symbol: GDF1
  entrez: '2657'
- word: ActB
  symbol: ACTB
  source: hgnc_symbol
  hgnc_symbol: ACTB
  entrez: '60'
- word: TGF-B2
  symbol: TGFB2
  source: hgnc_symbol
  hgnc_symbol: TGFB2
  entrez: '7042'
- word: (ALK4,
  symbol: ALK4
  source: hgnc_alias_symbol
  hgnc_symbol: ACVR1B
  entrez: '91'
- word: ALK5,
  symbol: ALK5
  source: hgnc_alias_symbol
  hgnc_symbol: TGFBR1
  entrez: '7046'
- word: (ALK4,ALK5,ALK7)
  symbol: ALK5
  source: hgnc_alias_symbol
  hgnc_symbol: TGFBR1
  entrez: '7046'
- word: (ALK4,ALK5,ALK7)
  symbol: ALK7
  source: hgnc_alias_symbol
  hgnc_symbol: ACVR1C
  entrez: '130399'
- word: ALK7)
  symbol: ALK7
  source: hgnc_alias_symbol
  hgnc_symbol: ACVR1C
  entrez: '130399'
- word: p-SMAD2
  symbol: SMAD2
  source: hgnc_symbol
  hgnc_symbol: SMAD2
  entrez: '4087'
- word: p-SMAD3
  symbol: SMAD3
  source: hgnc_symbol
  hgnc_symbol: SMAD3
  entrez: '4088'
- word: SMAD4
  symbol: SMAD4
  source: hgnc_symbol
  hgnc_symbol: SMAD4
  entrez: '4089'
- word: SMAD4
  symbol: SMAD4
  source: hgnc_symbol
  hgnc_symbol: SMAD4
  entrez: '4089'
- word: ЕРО
  symbol: EPO
  source: hgnc_symbol
  hgnc_symbol: EPO
  entrez: '2056'
- word: Jak2
  symbol: JAK2
  source: hgnc_symbol
  hgnc_symbol: JAK2
  entrez: '3717'
- word: Jak2
  symbol: JAK2
  source: hgnc_symbol
  hgnc_symbol: JAK2
  entrez: '3717'
- word: STAT5
  symbol: STAT5
  source: bioentities_symbol
  hgnc_symbol: STAT5A
  entrez: '6776'
- word: STAT5
  symbol: STAT5
  source: bioentities_symbol
  hgnc_symbol: STAT5B
  entrez: '6777'
- word: STAT5
  symbol: STAT5
  source: bioentities_symbol
  hgnc_symbol: STAT5A
  entrez: '6776'
- word: STAT5
  symbol: STAT5
  source: bioentities_symbol
  hgnc_symbol: STAT5B
  entrez: '6777'
- word: STAT5
  symbol: STAT5
  source: bioentities_symbol
  hgnc_symbol: STAT5A
  entrez: '6776'
- word: STAT5
  symbol: STAT5
  source: bioentities_symbol
  hgnc_symbol: STAT5B
  entrez: '6777'
- word: BMP6
  symbol: BMP6
  source: hgnc_symbol
  hgnc_symbol: BMP6
  entrez: '654'
- word: HFE
  symbol: HFE
  source: hgnc_symbol
  hgnc_symbol: HFE
  entrez: '3077'
- word: HJV
  symbol: HJV
  source: hgnc_alias_symbol
  hgnc_symbol: HFE2
  entrez: '148738'
- word: HJV
  symbol: HJV
  source: hgnc_alias_symbol
  hgnc_symbol: HFE2
  entrez: '148738'
- word: MT2
  symbol: MT2
  source: hgnc_prev_symbol
  hgnc_symbol: MT2A
  entrez: '4502'
- word: HJV
  symbol: HJV
  source: hgnc_alias_symbol
  hgnc_symbol: HFE2
  entrez: '148738'
- word: TFR2
  symbol: TFR2
  source: hgnc_symbol
  hgnc_symbol: TFR2
  entrez: '7036'
- word: TFR1
  symbol: TFR1
  source: hgnc_alias_symbol
  hgnc_symbol: TFRC
  entrez: '7037'
- word: BMP6
  symbol: BMP6
  source: hgnc_symbol
  hgnc_symbol: BMP6
  entrez: '654'
- word: SMAD1,
  symbol: SMAD1
  source: hgnc_symbol
  hgnc_symbol: SMAD1
  entrez: '4086'
- word: SMAD1,SMAD5orSMAD8
  symbol: SMAD1
  source: hgnc_symbol
  hgnc_symbol: SMAD1
  entrez: '4086'
- word: SMAD5
  symbol: SMAD5
  source: hgnc_symbol
  hgnc_symbol: SMAD5
  entrez: '4090'
- word: SMAD8
  symbol: SMAD8
  source: hgnc_alias_symbol
  hgnc_symbol: SMAD9
  entrez: '4093'
- word: JAK
  symbol: JAK
  source: bioentities_symbol
  hgnc_symbol: JAK1
  entrez: '3716'
- word: JAK
  symbol: JAK
  source: bioentities_symbol
  hgnc_symbol: JAK2
  entrez: '3717'
- word: JAK
  symbol: JAK
  source: bioentities_symbol
  hgnc_symbol: JAK3
  entrez: '3718'
- word: JAK
  symbol: JAK
  source: bioentities_symbol
  hgnc_symbol: TYK2
  entrez: '7297'
- word: IL-6
  symbol: IL-6
  source: hgnc_alias_symbol
  hgnc_symbol: IL6
  entrez: '3569'
- word: STAT3
  symbol: STAT3
  source: hgnc_symbol
  hgnc_symbol: STAT3
  entrez: '6774'
- word: SMAD4
  symbol: SMAD4
  source: hgnc_symbol
  hgnc_symbol: SMAD4
  entrez: '4089'
- word: IL-6
  symbol: IL-6
  source: hgnc_alias_symbol
  hgnc_symbol: IL6
  entrez: '3569'
- word: HAMP
  symbol: HAMP
  source: hgnc_symbol
  hgnc_symbol: HAMP
  entrez: '57817'
- word: ERFE
  symbol: ERFE
  source: hgnc_symbol
  hgnc_symbol: ERFE
  entrez: '151176'
chemicals:
- word: Fe (III)
  source: MESH
  identifier: D007501
diseases: []
figid_alias: PMC7299245__F1
redirect_from: /figures/PMC7299245__F1
figtype: Figure
---
